CalAmp CAMP Business Segments — Clinical and preclinical expenses

Similar metrics at other companies

GERNResearch and clinical expenses — R&D

$13M-5.1%

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

LBR

LBRXPreclinical — Direct Research And Development Expenses

$32.25K-93.0%

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

RNTXPreclinical Study Costs — Research And Development Expense

$0-100%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

Questions, answered.

What is CalAmp's business segments — clinical and preclinical expenses?

CalAmp (CAMP) reported business segments — clinical and preclinical expenses of $4.63M in Q1 2026.

How has CalAmp's business segments — clinical and preclinical expenses changed year-over-year?

CalAmp's business segments — clinical and preclinical expenses increased by 3.4% year-over-year, from $4.48M to $4.63M.

What is the long-term trend for CalAmp's business segments — clinical and preclinical expenses?

Over 2 years (2023 to 2025), CalAmp's business segments — clinical and preclinical expenses has grown at a -7.0% compound annual growth rate (CAGR), from $20.01M to $17.32M.

What does business segments — clinical and preclinical expenses mean?

This metric tracks the direct costs associated with conducting laboratory research, preclinical studies, and clinical trials for the company's therapeutic candidates. It is a critical measure of the capital intensity required to move drug candidates through the regulatory development lifecycle.